Table 3.

Meta-analysis results.

AEs	Number of included studies	Sample size	P	I 2	t 2	Effect of model	R% (95%CI)
Overall rate of AEs	11	819	<0.01	97%	0.026	Random	83.51% (95% CI: 73.55%–93.46%)
Serious AEs	10	791	<0.01	95%	0.071	Random	33.04% (18.15%–49.91%)
Definite Nusinersen-related AEs	8	498	<0.01	84	0.026	Random	0.57% (0–3.97%)
Probable Nusinersen-related AEs	8	498	<0.01	88	0.038	Random	7.76% (1.85%–17.22%)
Upper respiratory tract infection	9	577	<0.01	83	0.022	Random	39.94% (29.43%–50.94%)
Pneumonia	7	576	<0.01	79	0.013	Random	26.62% (17.99% –36.25%)
Vomiting	11	619	<0.01	76	0.016	Random	21.04% (14.15%–28.89%)
Constipation	9	482	<0.01	82	0.02	Random	19.59% (10.23%–31.09%)
Diarrhea	3	64	0.97	0	0	Fixed	28.11% (17.86%–39.67%)
Fever	11	763	<0.01	94	0.066	Random	40.07% (25.14%–56.02%)
Pain	8	608	<0.01	76	0.013	Random	22.75% (15.25%–31.25%)
Cough	7	488	<0.01	85	0.024	Random	31.81% (20.32%–44.57%)
Respiratory failure	6	440	0	65	0.08	Random	18.77% (11.9%–26.77%)
Gastroesophageal reflux disease	4	142	<0.01	78	0.028	Random	10.08% (1.78%–24.02%)
Atelectasis	4	399	<0.01	91	0.043	Random	16.2% (3.71%–35.17%)
Dysphagia	2	99	0.48	0	0	Fixed	8.98% (4.18%–15.37%)
Aspiration pneumonia	4	189	<0.01	0	0	Fixed	17.83% (11.13%–25.71%)
Respiratory distress	4	359	0.1	53	0.05	Random	17.83% (11.13%–25.71)
Nasopharyngitis	5	388	<0.01	83	0.022	Random	21.19% (10.38%–34.58%)
Skin rash	4	194	<0.01	94	0.104	Random	7.16% (0–31.82%)
Otitis media	4	148	<0.01	93	0.115	Random	12.56% (0.03%–42.34%)
Thrombocytopenia	6	442	<0.01	92	0.047	Random	1.81% (0–9.95%)
Post–lumbar puncture syndrome	11	828	<0.01	78	0.01	Random	14.16% (9.13%–20.1%)
motor milestone change	7	350	<0.01	95	0.098	Random	61.38% (37.60%–82.58%)

AEs, adverse events.